Brooks Laboratories Ltd.(NSE: BROOKS) Ltd. : Q3 FY23 Results Out; Total Income fell 20% YoY

Brooks Laboratories Limited (NSE: BROOKS) is a pharmaceutical contract research and manufacturing services company based in India. It offers a range of products catering to critical care segment in Parental Section, such as Beta Lactam, Cephalosporin and General Dry powder Injectables, Ampoules and Liquid vials, and Dry Syrups and Tablets. The company manufactures a range of products on a third-party basis for several pharmaceutical companies. Its product portfolio includes 26 dry powder injections, 31 liquid injections, five tablets, and two dry syrups, including Carbapenems products like Inj Ertapenem and Inj Meropenem, and Liquid Injectables such as Inj Nandrolone Decanoate, Inj Aceclofenac, and Inj Midazolam.

The company’s revenue from operations for Q3FY23 was 15.39 crore, while its total income was 15.40 crore. The company’s total expenses for the quarter were 26.93 crore, resulting in a net loss of 9.48 crore. The earnings per share (EPS) for the quarter was Rs. 2.03. The company’s revenue from operations decreased from the previous quarter, which was 18.08 crore in Q2FY23. The total income for Q3FY23 also decreased from the previous quarter, which was 18.2 crore in Q2FY23. The decrease in revenue and total income could be attributed to various factors such as a decrease in sales, lower prices of products, or increased competition in the market.

Brooks Laboratories Ltd. reported a decrease in revenue, total income, and net profit, as well as an increase in total expenses for Q3FY23 compared to the previous quarter. The company will need to implement measures to increase revenue and decrease expenses to improve its financial performance in the coming quarters.